People living with mycosis fungoides (MF) and Sézary syndrome (SS) can experience unique journeys, and each person’s treatment goals may vary. But you may have decided it’s time for something different because of one or more of the reasons described below.
Your current treatment(s) may not be working as well as it did before, has stopped working altogether, and/or has caused bothersome side effects
You have noticed new or worsening skin symptoms and/or test results have shown that your disease has spread beyond the skin to other areas of your body
Your disease is affecting your life, and you are ready to try a different treatment
If this sounds like you, don’t lose hope. POTELIGEO may offer you something different. Keep reading to learn what POTELIGEO is, how it may help, and how it works in the body.
POTELIGEO is a
Because POTELIGEO is an IV infusion, it will be given at an infusion center by a trained healthcare provider.Learn more about the infusion experience
POTELIGEO was studied in the largest clinical trial to date for a systemic treatment for people with the most common cutaneous T-cell lymphoma (CTCL) subtypes MF and SS. The phase 3 clinical trial evaluated the safety and effectiveness of treatment with POTELIGEO compared with the safety and effectiveness of a comparator treatment (vorinostat), which is a drug used in the United States to treat CTCL.
The clinical trial looked at the 4 areas of the body where disease could be found: skin, blood, lymph nodes, and internal organs. (Your healthcare provider may also refer to these areas of the body as "compartments.")
The clinical trial evaluated how well treatment prevented MF and SS from spreading further. Your healthcare provider may also refer to this as "progression-free survival."
In the clinical trial, people taking POTELIGEO experienced control over their disease for more than twice as long as those taking the comparator treatment.
Median number of months that MF or SS was controlled before showing any sign of spreading further
The clinical trial evaluated how well treatment reduced MF and SS in areas of the body where disease was found when entering the trial. Your healthcare provider may also refer to this as "response to treatment" or "overall response rate."
In the clinical trial, response to treatment was divided into 2 categories: partial response and complete response. Partial response is defined as a reduction in the amount of cancer in the body; complete response is defined as no evidence of disease in the body.
Percentage of people who experienced partial response in 1 or more areas of the body (skin, blood, lymph nodes, and internal organs) or complete response
2% of people who used POTELIGEO experienced complete response vs zero taking the comparator treatment
The clinical trial evaluated how long people responded to treatment. Your healthcare provider may also refer to this as "duration of response."
Response to treatment lasted 54% longer in people taking POTELIGEO vs those taking the comparator treatment.
Median number of months of partial or complete response (once response was first detected)
POTELIGEO is a monoclonal antibody that binds to certain cancerous T-cells, triggering your body’s immune cells to specifically target them. No other treatment for MF and SS works exactly the same way; let's take a closer look.
You’re signed up to receive the latest information on your disease and POTELIGEO. Check your inbox for a confirmation email.
Sign up to receive information and resources about your disease and POTELIGEO. Simply fill out the form below.